Emil von Behring and serum therapy

Winau, Florian; Winau, Rolf

doi:10.1016/s1286-4579(01)01526-x

Cited by 77 publications

(31 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…von Behring received the first ever Nobel prize in Medicine in 1901 "for his work on serum therapy and especially for its use against diphtheria, with which he opened up a new path in the field of medical science and gave the physician a powerful weapon with which to combat disease and death" (Winau andWinau, 2002), In 1913, von Behring developed the vaccine against DT, with widespread vaccinations beginning in 1920.…”

Section: History Of Diphtheriamentioning

confidence: 99%

Adhesion by Pathogenic Corynebacteria

Rogers

Das

Ton‐That³

2011

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Pathogenic members of the genus Corynebacterium cause a wide range of serious infections in humans including diphtheria. Adhesion to host cells is a crucial step during infection. In Corynebacterium diphtheriae, adhesion is mediated primarily by filamentous structures called pili or fimbriae that are covalently attached to the bacterial cell wall. C. diphtheriae produces three distinct pilus structures, SpaA-, SpaD- and SpaH-type pili. Similar to other types, the prototype SpaA pilus consists of SpaA forming the pilus shaft and two minor pilins SpaB and SpaC located at the base and at the tip, respectively. The minor pilins SpaB/SpaC are critical for bacterial binding to human pharyngeal cells, and thus represent the major adhesins of corynebacteria. Like pili of many other gram-positive microbes, the assembly of corynebacterial pili occurs by a two-step mechanism, whereby pilins are covalently polymerized by a transpeptidase enzyme named pilin-specific sortase and the generated pilus polymer is subsequently anchored to the cell wall peptidoglycan via the base pilin by the housekeeping sortase or a non-polymerizing sortase. This chapter reviews the current knowledge of corynebacterial adhesion, with a specific focus on pilus structures, their assembly, and the mechanism of adhesion mediated by pili.

show abstract

Section: History Of Diphtheriamentioning

confidence: 99%

Adhesion by Pathogenic Corynebacteria

Rogers

Das

Ton‐That³

2011

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

show abstract

“…Then after short time in Bonn, he moved to Berlin, where he worked under Koch and finally became the director of the Institute of Hygiene in Marburg. This part of his biography is, however, well described elsewhere (MacNalty 1954;Browning 1955;Winau & Winau 2002;Linton 2005;Simon 2007). …”

Section: Less Known Aspects Of His Biographymentioning

confidence: 84%

Little known ophthalmic interests of Emil von Behring, the first Nobel Prize Laureate in Medicine or Physiology

Grzybowski¹,

Wilhelm

2012

Acta Ophthalmologica

View full text Add to dashboard Cite

. Although the work for which Emil von Behring (1854–1917) was awarded the first Nobel Prize Winner for Medicine or Physiology in 1901 was on serum therapy, not only was he trained and worked as an ophthalmologist but he also wrote his doctoral dissertation on a practical ophthalmological topic whilst in Berlin under Carl Schweigger (1830–1905). He later worked for 3 years as an assistant and co‐worker with the famous Polish ophthalmologist Boleslaw Wicherkiewicz (1847–1915), in Poznan where he described an interesting ophthalmic case in a scientific journal. His life and work in other fields have been well studied, but his interests and relationship to ophthalmology that played an important role in, at least part of, Behring’s life have never previously been analysed thoroughly.

show abstract

“…Antibody therapy against infectious diseases was discovered by the German physiologist, Emil Adolf von Behring a century ago [7,8]. His work led to the first instance of industrial production of protective serum from horses in 1893 and to his receipt in 1901 of the first Nobel Prize in medicine.…”

Section: Animal Anti-serummentioning

confidence: 99%

Opportunities and Challenges of Therapeutic Monoclonal Antibodies as Medical Countermeasures for Biodefense

Hu¹,

Nagata²

2016

J Bioterror Biodef

View full text Add to dashboard Cite

Antibodies, naturally produced in the body as part of the immune response to infectious agents, can also be introduced artificially to treat infectious diseases. Advances in biotechnology in the last decades have made human or humanized monoclonal antibodies (mAbs) as therapeutics possible. These therapeutic mAbs currently enjoy unprecedented success and recognition of their potential. Unlike vaccines, therapeutic mAbs can confer instant and consistent protection against bio-threat agents when administered regardless of the recipient's immune status. Therapeutic mAbs can be administered in higher levels than those elicited by vaccines, and thus provide a higher level of protection or treatment that is necessary in a biological attack where people are exposed to a higher exposure of agent concentration than that found in nature. Furthermore, therapeutic mAbs have substantial advantages over antimicrobial drugs, such as high specificity, low systemic toxicity, relatively long half-life, and no concerns over disrupting the body's microbiome. Therapeutic mAbs can be used for both pre-and post-exposure protection; therefore, they have great value as effective medical countermeasures (MedCMs) against bio-threat agents. However, there are still some challenges to be overcome before therapeutic mAbs become ideal MedCMs against bio-threat agents. In this review, both opportunities and challenges in development of therapeutic mAbs are discussed.

show abstract

Emil von Behring and serum therapy

Cited by 77 publications

References 3 publications

Adhesion by Pathogenic Corynebacteria

Adhesion by Pathogenic Corynebacteria

Little known ophthalmic interests of Emil von Behring, the first Nobel Prize Laureate in Medicine or Physiology

Opportunities and Challenges of Therapeutic Monoclonal Antibodies as Medical Countermeasures for Biodefense

Contact Info

Product

Resources

About